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Abstract
Background: The spleen plays a pivotal role in the rapid clearance of parasitized red blood cells in patients with
falciparum malaria after artemisinin treatment. Prolonged parasite clearance can be found in patients who have had
a splenectomy, or those with hemoglobin abnormalities and/or reduced immunity, which are all distinguishable
from artemisinin resistance. This paper reports on a case of prolonged parasite clearance in a Chinese
splenectomized patient with falciparum malaria imported from Nigeria.
Case presentation: A 35-year-old Chinese male suffered 2 days of febrile illness after returning to Zhumadian city
of Henan province from Nigeria on October 1, 2014. The main symptoms were febrile, including the highest axillary
temperature of 40 °C, headache, and chills. A peripheral blood smear showed parasitemia (53 913 asexual parasites/
μl) of Plasmodium falciparum. The patient had not used any chemoprophylaxis against malaria in Nigeria when he
worked there as a construction worker between 2009 and 2014. The patient had three episodes of malaria in
Nigeria and had a splenectomy due to a traffic accident 8 years ago from the time he was admitted to hospital.
The patient was orally administrated a total of 320 mg/2.56 g dihydroartemisinin-piperaquine for 2 days and
intravenously administrated a total of 3 000 mg artesunate for 18 days. The axillary temperature of the patient
ranged between 37.0 and 37.7 °C from Day 0 to Day 3, and blood microscopy revealed falciparum malaria
parasitemia (26 674 asexual parasites/μl) on Day 3. The patient was afebrile on Day 4, falciparum malaria parasitemia
was continuously present and then gradually decreased on the next days, and was negative on Day 21. The patient
was cured and left hospital on Day 24 after no plasmodium falciparum was found in the blood on Day 21 to Day
23. No mutation was found in the K13 propeller gene when compared with the PF3D7_1343700 K13 propeller
gene reference sequence.
Conclusions: This is the first reported case in China of prolonged parasite clearance in a splenectomized patient
with imported falciparum malaria. Artemisinin resistance should be distinguished when prolonged parasite
clearance is found in a malaria patient who has had splenectomy.
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Background
In humans, the spleen is the largest secondary immune
organ in the body. Important functions of the spleen in-
clude removal of old and abnormal blood cells, removal
of circulating pathogens, and facilitating the develop-
ment of immune responses against Plasmodium [1]. It
has been shown that the spleen plays an active role in
the retention and removal of malaria-infected red blood
cells (RBCs) from blood circulation, as well as a key role
in the development of immune responses directed
against parasites [2]. Parasite clearance rates are influ-
enced by many factors, including insufficient artesunate
and dihydroartemisinin levels in the blood, pharmaco-
kinetics, pharmacodynamics, splenectomy, hemoglobin
abnormalities, and reduced immunity, which may delay
parasite clearance [3, 4]. The World Health Organiza-
tion’s (WHO’s) classification of antimalarial drug efficacy
(parasitemia on Day three with axillary temperature ≥
37.5 °C) [5] may not apply to asplenic patients. This
paper reports a case of prolonged parasite clearance in a
splenectomized Chinese worker with falciparum malaria
imported from Nigeria.
Case presentation
A 35-year-old Chinese male was admitted to the 6th
People’s Hospital in Zhengzhou, China on October 6, 2014,
because he had a fever with the highest axillary temperature
of 40 °C, headache, and chills. Prior to admission, the
patient had suffered 2 days of febrile illness after returning
from Nigeria on October 1, 2014. The patient had not used
chemoprophylaxis against malaria in Nigeria when he
worked there as a construction worker between 2009 and
2014. The patient had three episodes of malaria and had
been administrated quinine, but stopped treatment as soon
as he was afebrile. The patient also had a splenectomy due
to a traffic accident 8 years ago from the time he was
admitted to hospital.
Upon admission, the patient’s axillary temperature was
37.2 °C, his pulse rate was 75 beats/min, his blood pres-
sure was 93/79 mmHg, and his weight was 86 kg. Initial
laboratory test results were almost normal except for a
high C-reactive protein level of 35.8 mg/L and a low
kalaemia level of 3.30 mmol/L (see Table 1). Giemsa-
stained thick and thin blood films were microscopically
examined and the peripheral blood smear showed para-
sitaemia of Plasmodium falciparum. Microscopy experts
at the Henan Center for Disease Control and Prevention
confirmed this result. The density of malarial parasites
was 53 913 asexual parasites/μl on Day 0. A rapid diag-
nostic test (Wondfo Biotech Co., Ltd, China) was also
positive for malarial antigen. DNA of P. falciparum was
identified by nested polymerase chain reaction (PCR)
amplification of the small-subunit ribosomal ribonucleic
acid (18ssrRNA) genes. The K13 propeller gene was
amplified using nested PCR and sequenced. No
mutations were found when this gene was compared to
the PF3D7_1343700 K13 propeller gene reference
sequence retrieved from the National Center for
Biotechnology Information (NCBI) database.
The patient was intravenously administered artesunate
(120 mg first time; then 60 mg every six hours) for 4 days
and intravenously treated with the antibiotic ceftriaxone
(2.0 g per day) for 4 days. After 72 hours of treatment,
the axillary temperature of the patient was 37.4 °C and
Table 1 Pre-treatment blood result
Variable Value Reference value
Hematology
Leukocytes 6.93 × 109/L 4–10 × 109/L





Erythrocytes 5.08 × 1012/L 3.5–5.5 × 1012/L
Hemoglobin 155 g/L 110–160 g/L
Hematocrit 46% 36–50%
Platelets 192 × 109/L 100–300 × 109/L
HCT 46.40 36.6–50%
MCV 89.70 86–100 fl
MCH 30.80 26–31 pg
MCHC 343.00 310–370 g/L
Blood chemistry
AST 18 IU/L <40
ALT 40 IU/L <40
LDH 151 IU/L 110–240
γ-GTP 47 IU/L <40
Total bilirubin 14.2 μmol/L 3.0–21.0
BUN 4.5 mmol/L 3.2–7.1
Creatinine 91 μmol/L 44–133
Uric acid 282 μmol/L 201–430
Sodium 134 mmol/L 135–145
Potassium 3.30 mmol/L 3.5–5.5
Chloride 97 mmol/L 98–110
CRP 35.8 mg/L 0.10–8.20
Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase,
BUN blood urea nitrogen, CRP C-reactive protein, HCT Hematocrit, LDH lactic
dehydrogenase, MCH mean corpuscular hemoglobin, MCHC mean corpuscular
hemoglobin concentration, MCV erythrocyte mean corpuscular volume, γ-GTP
gamma-glutamyl transpeptidase
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the density of falciparum parasites was 26 674 asexual
parasites/μl (see Table 2). The patient was continu-
ously intravenously administered artesunate (60 mg
every 8 h for 9 days; 60 mg every 12 h for 1 day;
60 mg every day for 4 days) with antibiotic ceftriax-
one of 2.0 g per day for 14 days. The patient was
afebrile on Day 4 but blood microscopy revealed the
continuous presence of parasitaemia with densities
between 16 133 and 34 356 asexual parasites/μl. The
patient was orally administrated dihydroartemisinin-
piperaquine (40 mg/0.32 g per tablet, two tablets
twice per day) for 2 days from Day 10. The parasit-
emia declined slowly and morphology of the parasites
in the blood films, with pyknotic nuclei and shrunken
cytoplasm, suggested that they were dead. Falciparum
parasitaemia was negative on Day 21. The patient was
cured and left hospital on Day 24 after no plasmo-
dium falciparum was found in the blood on Day 21
to Day 23.
Discussion
Malaria had a wide geographical distribution in China
but this has decreased dramatically due to the strength-
ening of malaria control measures in recent decades,
especially in the Yunnan and Hainan provinces, and
Huanghuai region [6–8]. No locally transmitted malaria
cases have been reported since 2012, but imported mal-
aria has increased remarkably in Henan, which may
cause secondary spread and antimalarial drug resistance.
In 2014, 216 imported malaria cases were reported,
which was 24 times higher than the nine imported cases
in 2005 in this province [9]. With increasing travel and
migration, imported malaria has become a major public
health challenge [10–12] and poses a severe threat to
the malaria elimination program in China [13]. The
WHO currently recommends artemisinin-based combin-
ation therapies (ACTs) as the first-line treatment for
uncomplicated P. falciparum malaria [14], and oral
dihydroartemisinin-piperaquine tablets are most com-
monly used in China [15]. Typically, a 3-day treatment
course with an ACT reduces parasite densities and 95%
of patients’ malaria blood slide test results are negative
48 h after treatment [16]. The emergence of artemisinin
resistance, evidenced by delayed parasite clearance after
artemisinin treatment, poses a serious threat to the
global control of malaria. Artemisinin resistance is char-
acterized by a reduced susceptibility of the ring stage of
parasite development. It was first documented in west-
ern Cambodia [17, 18] and is now prevalent across an
expanding area of Southeast Asia, including in
Cambodia [19–21], Thailand [22, 23], and the Thai-
Myanmar border [24].
Over the past decade, African countries have transi-
tioned from using chloroquine or sulfadoxine-
pyrimethamine to ACTs as a first-line policy for treating
uncomplicated malaria [25]. Although ACT-resistant
malaria is rare in Africa, there is a historical precedence
of resistance to antimalarial medicine emerging in Asia
and spreading to Africa [26]. Three cases of early treat-
ment failure due to possible ACT-resistant P. falciparum
malaria have been reported in Nigeria [27]. There has
also been a case of possible artemether-lumefantrine
treatment failure in an Italian traveler with uncompli-
cated P. falciparum malaria imported from the Demo-
cratic Republic of the Congo [28]. Routine monitoring is
needed to ensure that the recommended first-line
ACTs are effective for timely changes in national
treatment policies and for the early detection of arte-
misinin resistance.
Prolonged parasite clearance is the basis for the
current WHO working definition of artemisinin resist-
ance [5] but it may not applicable for patients who have
had a splenectomy [29–31]. In the case reported in
this paper, blood microscopy revealed that falciparum
Table 2 Parasite density and body temperature of patient
during hospital stay
Day Temperature (°C) Parasite density
(asexual parasites/μl)
0 37.2 53 913
1 37.0 30 581
2 37.7 30 545
3 37.4 26 674
4 36.5 34 356
5 36.6 31 701
6 36.2 23 896
7 36.5 25 316
8 37.2 21 982
9 37.5 16 133
10 37.5 19 847
11 36.5 –
12 37.2 16 434
13 36.3 –
14 36.2 2 962
15 36.3 –
16 36.2 3 211
17 36.3 –
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parasitemia was continuously present and was negative on
Day 20 after artemisinin treatment. According to the
WHO classification of antimalarial drug efficacy (parasit-
emia on Day three with axillary temperature ≥ 37.5 °C) [5],
the patient was considered an early treatment failure for
the first time in China. Actually, it is caused by splenec-
tomy but not artemisinin resistance.
The spleen is responsible for initiating immune reac-
tions to blood-borne antigens and for filtering the blood
of foreign material, and old or damaged RBCs. It plays a
crucial role in the defense against infections with viruses,
bacteria, fungi, and parasites [32]. The spleen plays a
pivotal role in the rapid clearance of parasitized RBCs in
patients with falciparum malaria after artemisinin treat-
ment, and parasite clearance after artesunate treatment
can be markedly prolonged in falciparum malaria
patients who have had a splenectomy [33]. A previous
study showed that Plasmodium-infected erythrocytes
lose their normal deformability and become susceptible
to splenic filtration, and splenic clearance of erythrocytes
is enhanced by antimalarial therapy and splenomegaly
[34]. The intact splenic function is of utmost importance
for the host’s defense capacity against Plasmodium spp.,
not only because it limits the acute infection through
the removal of parasites from the blood stream, but also
because it modulates parasite antigen expression on the
surface of infected RBCs as well as cellular and humoral
immune responses [35]. Other causes of immune sup-
pression, such as cancer, may possibly reactivate latent
malaria parasites [36]. Falciparum malaria infection is
common in pregnant women and anemia is an import-
ant complication [37]. HIV infection may defects in
macrophage phagocytosis, which diminish the spleen’s
ability to clear infection, causes the rapid onset of
cerebral malaria in children [38].
The delay in parasite clearance has also been reported
in a splenectomized patient with P. knowlesi malaria
[39]. In a prospective controlled study of 33 previously
splenectomized Malawian adults, parasite densities of P.
falciparum reached significantly higher levels, and ma-
ture parasite stages were more often seen in the periph-
eral blood of asplenic individuals [40]. In areas endemic
for P. falciparum, fever and parasitemia are significantly
more frequent in splenectomized patients than in
spleen-intact patients [40–42]. Splenectomized patients
are at high risk of developing a more severe and fatal
disease, even if they acquired semi-immunity prior to
the loss of splenic tissue [29, 33, 35, 43]. In this case, the
patient’s main symptoms were fever and parasitemia.
The parasitemia declined slowly following artemisinin
treatment. The morphology of the parasites in the blood
films, with pyknotic nuclei and shrunken cytoplasm,
suggested that they were dead. Although drug-affected
parasites have clearly abnormal shapes, it is not easy to
distinguish live parasites from dead ones. Malaria para-
sites were observed in blood films until Day 21 after
continuous artemisinin treatment. Chotivanich et al.
reported that patients without a functional spleen who
have prolonged parasite clearance presumably do not
require additional antimalarial treatment [33].
Recently, a molecular marker of artemisinin resistance
was identified. Mutations in K13 propeller domain were
shown to be associated with delayed parasite clearance
in vitro and in vivo [44, 45]. The detection of molecular
mutations associated with K13 will greatly facilitate the
tracking of artemisinin resistance as it emerges. In the
case reported in this paper, prolonged parasite clearance
was found after treatment with artesunate and ACT.
The patient had a splenectomy due to a traffic accident
8 years ago from the time he was admitted to hospital
and no mutation was found in the K13 propeller gene.
Therefore, this case was finally identified as prolonged
parasite clearance by splenectomy.
Conclusion
This paper reports a case of prolonged parasite clearance
in a splenectomized Chinese worker with falciparum mal-
aria imported from Nigeria. Artemisinin resistance should
be distinguished when prolonged parasite clearance is
found in a malaria patient who has had splenectomy.
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